Merck & Co., Inc. is making its latest foray into drugs targeting a lysosomal ion channel that plays a role in neurodegenerative diseases with its acquisition of Caraway Therapeutics, a venture capital-backed company focused on Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and other rare diseases. In doing so, the pharma company is hoping to expand its presence in the area of neuroscience.
The Rahway, NJ-based drug maker announced on 21 November the acquisition of Caraway for up to $610m, which includes an undisclosed upfront payment and contingent milestone payments
Key Takeaways
-
Merck is putting down $610m to acquire venture capital-backed Caraway Therapeutics, in which its MRL Venture Fund has been a shareholder since 2018.
-
Caraway’s focus is on neurodegenerative diseases, with its lead preclinical assets targeting the TRPML1 pathway
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
